Search results
...Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of...
Morningstar· 5 hours agoGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors Glancy Prongay ...
European Commission grants marketing approval to Biogen's ALS drug
Reuters· 5 hours ago, opens new tab said on Thursday that the European Commission has granted marketing authorization...
... Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit...
Morningstar· 7 hours agoPomerantz LLP announces that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) and certain officers. The class action, filed ...
Is Biogen Inc.'s (NASDAQ:BIIB) Recent Price Movement Underpinned By Its Weak Fundamentals?
Simply Wall St. via Yahoo Finance· 3 days agoIt is hard to get excited after looking at Biogen's (NASDAQ:BIIB) recent performance, when its stock...
Biogen Inc. (Nasdaq: BIIB) Investors Notice: Class action lawsuit filed on behalf of investors; the...
Morningstar· 1 day agoInvestors can contact the law firm at no cost to learn more about recovering their losses. LOS ANGELES, May 29, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Biogen Inc. (Nasdaq: < ...
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a...
Morningstar· 8 hours agoBiogen Inc. (Nasdaq: BIIB) announced the European Commission (EC) has granted marketing authorization under exceptional circumstances and maintained orphan designation for ...
BIIB INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with...
Benzinga· 6 days agoRudman & Dowd LLP announces that purchasers or acquirers of Biogen Inc. BIIB securities between February 3, 2022 and February 13, 2024, both dates inclusive (the "Class Period ...
RBC maintains $317 price target on Biogen stock, cites Skyclarys importance By Investing.com
Investing.com· 2 days agoOn Wednesday, RBC (TSX:RY) Capital maintained its Outperform rating on Biogen (NASDAQ:BIIB) shares...
Why Is Biogen (BIIB) Up 7.7% Since Last Earnings Report?
Zacks via Yahoo Finance· 7 days agoA month has gone by since the last earnings report for Biogen Inc. (BIIB). Shares have added about...
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar...
Zacks via Yahoo Finance· 7 days agoStocks recently featured in the blog include: Biogen BIIB, Ionis Pharmaceuticals IONS, GSK plc GSK,...